Keyphrases
Adipose Tissue Thickness
33%
ANOVA Test
16%
Anti-inflammation
16%
Anti-inflammatory Role
16%
Atherogenesis
16%
Atherosclerosis Development
100%
Blood Glucose
16%
Darapladib
100%
Diabetes Mellitus Model
100%
Diabetes Type 1
16%
Early Atherosclerosis
100%
Experimental Facility
16%
Group Design
16%
In Vivo Model
33%
In Vivo Rat
100%
Inducible Nitric Oxide Synthase
33%
Inflammation Level
100%
Inflammation Markers
16%
Inflammatory Effects
16%
Insulin Plasma
16%
Insulin Resistance
16%
Interleukin-6
33%
LDL Levels
16%
Lipid Profile
16%
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
33%
Lysophosphatidylcholine
16%
Normal Type
16%
Oxidative Stress
16%
Oxidized Fatty Acids
16%
Oxidized Low-density Lipoprotein (ox-LDL)
50%
Perivascular Adipose Tissue
33%
Plasma Parameters
16%
Platelet-activating Factor
50%
Selective Inhibitor
16%
Time-to-treatment
16%
Tissue Damage
16%
Tumor Necrosis Factor-α
16%
Type 2 Diabetes Melitus
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Vascular Inflammation
16%
INIS
adipose tissue
33%
administration
16%
atherosclerosis
100%
blood
33%
control
16%
damage
16%
design
16%
diabetes mellitus
100%
fatty acids
16%
glucose
16%
in vivo
100%
inflammation
100%
insulin
33%
interleukins
33%
interventions
16%
laboratories
16%
levels
100%
lipids
16%
lipoproteins
33%
nitric oxide
33%
oxidation
16%
plasma
16%
rats
100%
thickness
33%
tissues
33%
tumor necrosis factor
16%
Pharmacology, Toxicology and Pharmaceutical Science
1 Alkyl 2 Acetylglycerophosphocholine Esterase
28%
Anti-Inflammation
14%
Anti-Inflammatory Drug
14%
Atherogenesis
14%
Atherosclerosis
100%
Darapladib
100%
Fatty Acid
14%
Inducible Nitric Oxide Synthase
28%
Inflammation
100%
Insulin Resistance
14%
Interleukin 6
28%
Lysophosphatidylcholine
14%
Non Insulin Dependent Diabetes Mellitus
100%
Oxidized Low Density Lipoprotein
14%
Thrombocyte Activating Factor
42%
Tissue Injury
14%
Tumor Necrosis Factor
14%
Vasculitis
14%